W. Timothy Garvey, MD

Timothy Garvey, MD, discusses petrelintide’s efficacy in patients with overweight and obesity, as well as its comparably low incidence of gastrointestinal effects.

This World Obesity Day, catch up on major paradigm shifts in the diagnosis, discussion, and treatment of obesity, one of the world’s most devastating chronic diseases.

With the FDA approval of oral semaglutide, Garvey weighs safety, oversight, and the future direction of GLP-1 weight management therapy.

Garvey reflects on the recent FDA approval of oral semaglutide (Wegovy) as the first GLP-1 pill for weight loss.

Explore groundbreaking findings from the REDEFINE trials on CagriSema's impact on weight loss and diabetes management at ADA 2025.

From barriers to implementing evidence-based care to innovations in combination therapy, here are 5 key updates from the annual meeting.

The recent Lancet Commission on Obesity has repositioned the former risk factor as a disease, indicating and emphasizing a variety of complications.